Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 57.35
(4.08%)
HKD 57.35
(4.08%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 945.34 Million CNY | -37.41% |
| 2022 | 1.51 Billion CNY | 8.19% |
| 2021 | 1.39 Billion CNY | 92.2% |
| 2020 | 726.38 Million CNY | 61.86% |
| 2019 | 448.78 Million CNY | 5.82% |
| 2018 | 424.11 Million CNY | 62.98% |
| 2017 | 260.22 Million CNY | 18.96% |
| 2016 | 218.75 Million CNY | 69.56% |
| 2015 | 129.01 Million CNY | 10.19% |
| 2014 | 117.08 Million CNY | -19.9% |
| 2013 | 146.16 Million CNY | 6.33% |
| 2012 | 137.46 Million CNY | 5.88% |
| 2011 | 129.83 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 992.33 Million CNY | 4.97% |
| 2024 Q2 | 997.95 Million CNY | 0.57% |
| 2024 Q3 | 1.19 Billion CNY | 20.04% |
| 2023 Q4 | 945.34 Million CNY | 7.38% |
| 2023 Q2 | 788.02 Million CNY | -28.88% |
| 2023 FY | 945.34 Million CNY | -37.41% |
| 2023 Q3 | 880.35 Million CNY | 11.72% |
| 2023 Q1 | 1.1 Billion CNY | -26.64% |
| 2022 Q3 | 1.66 Billion CNY | -12.23% |
| 2022 FY | 1.51 Billion CNY | 8.19% |
| 2022 Q4 | 1.51 Billion CNY | -9.46% |
| 2022 Q2 | 1.9 Billion CNY | 11.3% |
| 2022 Q1 | 1.7 Billion CNY | 22.31% |
| 2021 Q1 | 800.49 Million CNY | 10.2% |
| 2021 Q2 | 878.98 Million CNY | 9.81% |
| 2021 Q4 | 1.39 Billion CNY | 28.9% |
| 2021 FY | 1.39 Billion CNY | 92.2% |
| 2021 Q3 | 1.08 Billion CNY | 23.22% |
| 2020 Q3 | 672.71 Million CNY | 18.46% |
| 2020 Q1 | 531.33 Million CNY | 18.4% |
| 2020 Q4 | 726.38 Million CNY | 7.98% |
| 2020 Q2 | 567.87 Million CNY | 6.88% |
| 2020 FY | 726.38 Million CNY | 61.86% |
| 2019 FY | 448.78 Million CNY | 5.82% |
| 2019 Q2 | 426.17 Million CNY | -8.44% |
| 2019 Q1 | 465.44 Million CNY | 9.74% |
| 2019 Q3 | 449.39 Million CNY | 5.45% |
| 2019 Q4 | 448.78 Million CNY | -0.14% |
| 2018 Q2 | 339.44 Million CNY | 8.47% |
| 2018 FY | 424.11 Million CNY | 62.98% |
| 2018 Q4 | 424.11 Million CNY | 11.44% |
| 2018 Q3 | 380.57 Million CNY | 12.12% |
| 2018 Q1 | 312.93 Million CNY | 20.26% |
| 2017 Q4 | 260.22 Million CNY | -1.22% |
| 2017 Q1 | 206.89 Million CNY | -5.42% |
| 2017 Q2 | 248.79 Million CNY | 20.26% |
| 2017 Q3 | 263.43 Million CNY | 5.88% |
| 2017 FY | 260.22 Million CNY | 18.96% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q3 | 245.73 Million CNY | 24.26% |
| 2016 Q4 | 218.75 Million CNY | -10.98% |
| 2016 Q2 | 197.75 Million CNY | 0.0% |
| 2016 FY | 218.75 Million CNY | 69.56% |
| 2015 FY | 129.01 Million CNY | 10.19% |
| 2015 Q4 | 129.01 Million CNY | 0.0% |
| 2014 FY | 117.08 Million CNY | -19.9% |
| 2013 FY | 146.16 Million CNY | 6.33% |
| 2012 FY | 137.46 Million CNY | 5.88% |
| 2011 FY | 129.83 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 36.39 Million HKD | -2497.679% |
| CK Life Sciences Int'l., (Holdings) Inc. | 1.2 Billion HKD | 21.518% |